Preliminary Study of Minimally Invasive Intracranial Hematoma Evacuation Surgery Combined with rt-PA in Patients with Spontaneous Intracerebral Hemorrhage

Li-fei LIAN,Feng XU,Qi-ming LIANG,Wen-hao ZHU,Chao PAN,Gang WANG,Yi-chi ZHANG,Fu-rong Wang,Zhou-ping TANG,Sui-qiang ZHU
DOI: https://doi.org/10.16780/j.cnki.sjssgncj.2018.03.002
2018-01-01
Abstract:Objective:To evaluate the feasibility and safety of minimally invasive intracranial hematoma suction drainage surgery (MIS) plus intraclot use of recombinant tissue-type plasminogen activator (rt-PA) in patients with spontaneous intracerebral hemorrhage (ICH) and to explore the potential treatment regimen of intraclot rt-PA. Methods: Patients with ICH treated with MIS and intraclot rt-PA were retrospectively identified. A volumetric analysis to assess hematoma and perihematomal edema (PHE) volumes was conducted. Glasgow Coma Score(GCS) was used to assess consciousness.The modified Rankin Scale(mRS)was used for scoring clinical outcomes (mRS 0~3 v.s. 4~5). The observed 30-day cohort mortality was compared with its predicted mortality.Results:Forty-five patients were included.The median number of doses and dose of rt-PA was 2(1) doses and 1.5(1)mg,with a maximum cumulative dose of 4.0 mg.The ICH volume and PHE volume post-MIS was significantly lower compared with that of pre-MIS, respectively (P=0.000; P=0.000). There was a significantly negative correlation between puncture accuracy and residual hematoma volume (ρ= -0.61;P<0.01).GCS at post-MIS was significantly higher than that at pre-MIS(P=0.000).The 30-day patient morality was 0,significantly lower than the predicted mortality(46.7%).No patients developed intracranial infection,and only 2 patients experienced rebleeding.The patients were followed up for a median of 2.5 years; 5 patients died, 3 patients lost contact,and 21 patients had good outcomes(mRS 0~3).Conclusion:MIS combined with low dose rt-PA in the treatment of ICH enhances clot evacuation,lowers 30-day mortality,and improves long-term clinical outcome. The rt-PA dosage regimen of 0.5~1.0 mg/12~24 h, ≤4.0 mg cumulative may be favorable for treatment in ICH patients receiving minimally invasive surgery.
What problem does this paper attempt to address?